Long-term outcome of percutaneous radiofrequency ablation for periportal hepatocellular carcinoma: tumor recurrence or progression, survival and clinical significance

Recent studies have suggested that periportal location of percutaneous radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC) is considered as one of the independent risk factors for local tumor progression (LTP). However, the long-term therapeutic outcomes of percutaneous RFA as the first...

Full description

Saved in:
Bibliographic Details
Published in:Cancer imaging 2022-01, Vol.22 (1), p.2-2, Article 2
Main Authors: Cao, Shoujin, Lyu, Tianshi, Fan, Zeyang, Guan, Haitao, Song, Li, Tong, Xiaoqiang, Wang, Jian, Zou, Yinghua
Format: Article
Language:English
Subjects:
Ablation
Ablation (Surgery)
Carcinoma, Hepatocellular - surgery
Care and treatment
Catheter Ablation
Chemoembolization, Therapeutic
Clinical significance
Development and progression
Diseases
Electrodes
Health aspects
Hepatocellular carcinoma (HCC)
Hepatoma
Humans
Liver cancer
Liver Neoplasms - surgery
Medical prognosis
Metastasis
Neoplasm Recurrence, Local
Patients
Periportal
Radio frequency
Radiofrequency Ablation
Radiofrequency ablation (RFA)
Relapse
Retrospective Studies
Risk analysis
Risk factors
Subgroups
Survival
Therapeutic outcomes
Therapy
Treatment Outcome
Tumor progression
Tumor recurrence
Tumors
Veins & arteries
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Recent studies have suggested that periportal location of percutaneous radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC) is considered as one of the independent risk factors for local tumor progression (LTP). However, the long-term therapeutic outcomes of percutaneous RFA as the first-line therapy for single periportal HCCand corresponding impacts on tumor recurrence or progression are still unclear. From February 2011 to October 2020, a total of 233 patients with single nodular HCC ≤ 5 cm who underwent RFA ± transarterial chemoembolization (TACE) as first-line therapy was enrolled and analyzed, including 56 patients in the periportal group and 177 patients in the nonperiportal group. The long-term therapeutic outcomes between the two groups were compared, risk factors of tumor recurrence or progression were evaluated. The LTP rates at 1, 3, and 5 years were significantly higher in the periportal group than those in the nonperiportal group (15.7, 33.7, and 46.9% vs 6.0, 15.7, and 28.7%, respectively, P = 0.0067). The 1-, 3- and 5-year overall survival (OS) rates in the periportal group were significantly worse than those in the nonperiportal group (81.3, 65.1 and 42.9% vs 99.3, 90.4 and 78.1%, respectively, P
ISSN:1470-7330
1740-5025
1470-7330
DOI:10.1186/s40644-021-00442-2